Philippe Martin was named Viatris' chief R&D officer, while Novartis and Teva are noted for drug approvals and generic production.
4 reports, 3 independent
Updated Jul 21
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Philippe Martin was named Viatris' chief R&D officer, while Novartis and Teva are noted for drug approvals and generic production.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Novartis CEO Vas Narasimhan expressed confidence in the company's long-term growth.Sub-event
Philippe Martin appointed Viatris' chief R&D officer.1 source
Keep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
-
Mylan
former pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaViatris’ blepharitis ointment fails Phase III trial Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider th
- StockStoryWhy Viatris (VTRS) Stock Is Falling Today Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory conditi
- PR NewswireViatris Provides Update on Phase 3 Study of MR-139 for Blepharitis PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomize
- Unknown outlet